Lorcaserin: balancing efficacy with potential risks

Lancet. 2018 Nov 24;392(10161):2239-2240. doi: 10.1016/S0140-6736(18)32460-7. Epub 2018 Oct 4.

Authors

Xabier Unamuno¹, Gema Frühbeck²

Affiliations

¹ Metabolic Research Laboratory, Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, IdiSNA, CIBEROBN, 31008 Pamplona, Spain.
² Metabolic Research Laboratory, Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, IdiSNA, CIBEROBN, 31008 Pamplona, Spain. Electronic address: gfruhbeck@unav.es.

PMID: 30293772
DOI: 10.1016/S0140-6736(18)32460-7

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Benzazepines
Camellia*
Diabetes Mellitus, Type 2*
Humans
Obesity
Overweight

Substances

Benzazepines
lorcaserin